Cytokinetics to announce Phase 3 trial results for aficamten in non-obstructive hypertrophic cardiomyopathy on May 5, 2026

Cytokinetics will report topline results from its pivotal Phase 3 ACACIA-HCM trial of aficamten, a cardiac myosin inhibitor, in patients with non-obstructive hypertrophic cardiomyopathy on May 5, 2026. This announcement is significant as aficamten is already approved for obstructive hypertrophic cardiomyopathy in several regions. The company will hold a conference call and webcast to discuss the results, which could impact treatment options for this patient group. Investors and stakeholders can access the webcast via Cytokinetics' website, with a replay available for six months.